HomeAI · summaries
Storia in 4 fonti
India warns of misuse risk from cheap weight-loss jabs
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement across the pharmaceutical supply chain. The warning comes after patents on semaglutide — the active ingredient in drugs such as Ozempic and Wegovy — expired on March 20 in India, the world’s largest supplier of generic medicines. Generic versions of the GLP-1 drugs — referring to the hormone that regulates blood glucose levels and appetite — will slash costs and transform the global fight against obesity.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindu.com
Generic semaglutide widens access, but doctors warn of misuse and quality risks
Generic semaglutide increases accessibility, but doctors caution against misuse and quality concerns
- ·
cnbc.com
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to stay on top
Indian generic drugmakers launch a price war against Novo Nordisk’s GLP-1 brands, Ozempic and WeGovy.
- ·
arabnews.com
India warns of misuse risk from cheap weight-loss jabs
India’s health ministry warned Tuesday of the risks of unregulated use of weight-loss drugs, as low-cost generic versions hit the market, stepping up inspections and enforcement…
- ·
Centre intensifies regulatory surveillance over weight loss drugs
India intensifies regulatory measures on weight loss drugs to prevent unauthorized sales and ensure safe medical use.
- ·
India warns of misuse of low-cost weight-loss drugs as Ozempic generics enter market
NEW DELHI: India’s Health Ministry warned on Tuesday of the unregulated use of weight-loss drugs, as cheap generic versions of blockbuster diabetes medications such as Ozempic…
- ·
forbes.com
Indian Pharma Billionaires Pile Into Generic Weight-Loss Drugs, Sparking Regulatory Scrutiny
Last week’s expiry of the patent for semaglutide—the active ingredient in Novo Nordisk’s blockbuster drugs Wegovy and Ozmepic that are used to treat both diabetes and…